Diabetes
NEW STUDY COMING SOON
EFFICACY OF ORAL WEIGHT LOSS MEDICATION IN PERSONS WITH TYPE 2 DIABETES
Intro: This study will compare efficacy of different doses of a new oral GLP-1 medication to placebo for weight loss in overweight persons with Type 2 Diabetes.
Investigational Drug: A new once daily administered non-peptide agonist (NPA) of the GLP-1 receptor to reduce appetite and body weight compared to placebo.
To Qualify: Persons age 18 to 75 with Type 2 Diabetes, an HA1C of 7.0 to 10.5, currently treated with diet and exercise alone, or a stable dose of metformin.
Goal: To assess the effec of the investigational medication on weight loss and HA1C in persons with Type 2 Diabetes and overweight condition.